Walter W. Chen
Auto-generated profile, based on publicly available information

Walter W. Chen

Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2011 in Nature
Verified
Journal Article
Open access
PDF file
RPRichard Possemato
Richard Possemato
KMKevin M. Marks
Kevin M. Marks
YSYoav D. Shaul
Yoav D. Shaul
MPMichael E. Pacold
Michael E. Pacold
DKDohoon Kim
Dohoon Kim
DSDavid M. Sabatini
David M. Sabatini
An in vivo RNAi screen of metabolic enzymes and transporters is used to identify, among other genes, phosphoglycerate dehydrogenase (PHGDH) as a gene required for breast tumour growth. PHGDH resides in a region of chromosome 1p that is often amplified in breast cancers, leading to PHGDH overexpression. Elevated levels of PHGDH cause increased metabolic flux through the serine synthesis pathway, which in turn contributes significantly to the flux of glutamine to α-ketoglutarate through the tricarboxylic acid cycle. These observations suggest that targeting PHGDH or the serine biosynthesis pathway in general might be of therapeutic value in the subset of breast cancers with high PHGDH expression. Cancer cells adapt their metabolic processes to drive macromolecular biosynthesis for rapid cell growth and proliferation1,2. RNA interference (RNAi)-based loss-of-function screening has proven powerful for the identification of new and interesting cancer targets, and recent studies have used this technology in vivo to identify novel tumour suppressor genes3. Here we developed a method for identifying novel cancer targets via negative-selection RNAi screening using a human breast cancer xenograft model at an orthotopic site in the mouse. Using this method, we screened a set of metabolic genes associated with aggressive breast cancer and stemness to identify those required for in vivo tumorigenesis. Among the genes identified, phosphoglycerate dehydrogenase (PHGDH) is in a genomic region of recurrent copy number gain in breast cancer and PHGDH protein levels are elevated in 70% of oestrogen receptor (ER)-negative breast cancers. PHGDH catalyses the first step in the serine biosynthesis pathway, and breast cancer cells with high PHGDH expression have increased serine synthesis flux. Suppression of PHGDH in cell lines with elevated PHGDH expression, but not in those without, causes a strong decrease in cell proliferation and a reduction in serine synthesis. We find that PHGDH suppression does not affect intracellular serine levels, but causes a drop in the levels of α-ketoglutarate, another output of the pathway and a tricarboxylic acid (TCA) cycle intermediate. In cells with high PHGDH expression, the serine synthesis pathway contributes approximately 50% of the total anaplerotic flux of glutamine into the TCA cycle. These results reveal that certain breast cancers are dependent upon increased serine pathway flux caused by PHGDH overexpression and demonstrate the utility of in vivo negative-selection RNAi screens for finding potential anticancer targets.

1 July 2015 in Cell
Verified
Journal Article
Closed access
KBKıvanç Birsoy
Kıvanç Birsoy
TWTim Wang
Tim Wang
WCWalter W. Chen
Walter W. Chen
EFElizaveta Freinkman
Elizaveta Freinkman
MAMonther Abu-Remaileh
Monther Abu-Remaileh
DSDavid M. Sabatini
David M. Sabatini

31 May 2013 in Science
Verified
Journal Article
Closed access
PDF file
LBLiron Bar-Peled
Liron Bar-Peled
LCLynne Chantranupong
Lynne Chantranupong
ACAndrew D. Cherniack
Andrew D. Cherniack
WCWalter W. Chen
Walter W. Chen
KOKathleen A. Ottina
Kathleen A. Ottina
DSDavid M. Sabatini
David M. Sabatini
Limiting mTORC1: The mTORC1 protein kinase complex has important functions linking metabolism to cell growth and its functions are disrupted in common diseases, including cancer and diabetes. Bar-Peled et al. (p. 1100 ; see the Perspective by Shaw ) discovered regulatory components that help turn down signaling by mTORC1 when cells are deprived of amino acids. Two complexes of proteins, GATOR1 and GATOR2, have opposite effects on activity and cellular localization of mTORC1. Components of the GATOR1 complex negatively regulate mTORC1 and appear to function as tumor supressors. Cancers with loss of GATOR1 function may be particularly amenable to therapeutic strategies that limit activity of mTORC1.

16 March 2014 in Nature
Verified
Journal Article
Open access
PDF file
KBKıvanç Birsoy
Kıvanç Birsoy
RPRichard Possemato
Richard Possemato
FLFranziska K. Lorbeer
Franziska K. Lorbeer
Erol BayraktarErol Bayraktar
Erol Bayraktar
PTPrathapan Thiru
Prathapan Thiru
DSDavid M. Sabatini
David M. Sabatini
New apparatus is used to maintain proliferating cancer cells in low-glucose conditions, demonstrating that mitochondrial oxidative phosphorylation (OXPHOS) is essential for optimal proliferation in these conditions; the most sensitive cell lines are defective in OXPHOS upregulation and may therefore be sensitive to current antidiabetic drugs that inhibit OXPHOS. Using a new continuous-flow culture apparatus called Nutrostat, designed to ensure constant and controlled extracellular nutrient levels, David Sabatini and colleagues screened cancer cell lines for genes important when cells experience low glucose levels. They found that the ability of cells to increase mitochondrial oxidative phosphorylation under conditions of low glucose was crucial. Cancer cells unable to do so due to impaired glucose utilization or mitochondrial DNA mutations were particularly sensitive to a class of compounds, biguanides, which are in use to treat diabetes. These findings may lead to new therapeutic applications of these drugs to treat tumours displaying such defects. As the concentrations of highly consumed nutrients, particularly glucose, are generally lower in tumours than in normal tissues1,2, cancer cells must adapt their metabolism to the tumour microenvironment. A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit. Here we developed a continuous-flow culture apparatus (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions. Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose. We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization. These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS3,4, when cancer cells are grown in low glucose or as tumour xenografts. Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function5. Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.

1 February 2017 in Cell
Verified
Journal Article
Closed access
TWTim Wang
Tim Wang
HYHaiyan Yu
Haiyan Yu
NHNicholas W. Hughes
Nicholas W. Hughes
BLBingxu Liu
Bingxu Liu
AKArek Kendirli
Arek Kendirli
DSDavid M. Sabatini
David M. Sabatini

17 April 2015 in Science
Verified
Journal Article
Closed access
PDF file
PKPekka Katajisto
Pekka Katajisto
JDJulia Döhla
Julia Döhla
CCChristine L. Chaffer
Christine L. Chaffer
NPNalle Pentinmikko
Nalle Pentinmikko
NMNemanja Marjanovic
Nemanja Marjanovic
DSDavid M. Sabatini
David M. Sabatini
Stem cells can sort mitochondria by age: The renewal of tissues in aging organisms requires stem cells, which have the unusual ability to divide asymmetrically into one daughter cell that retains stem cell properties and another that differentiates into a particular tissue type. Katajisto et al. used photoactivated marker proteins to monitor the age of cell organelles in stemlike cells from human breast tissue and their distribution into daughter cells. Most organelles were evenly distributed, but daughter cells that maintained stem-cell properties received more newly produced mitochondria and fewer old ones. Science , this issue p. 340